Prognostic staging of extensively pretreated patients with advanced HIV-1 disease

HIV Clinical Trials

Volumn 6, Issue 6, 2005, Pages 281-290

  Montaner, Julio ^a   Guimaraes, Denise ^b   Chung, Jain ^b   Gafoor, Zarina ^c   Salgo, Miklos ^b   DeMasi, Ralph ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HOFFMANN LA ROCHE INC   (United States)

^c Trimeris Inc   (United States)

Author keywords

Enfuvirtide; HIV; Prognostic factors

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; TENOFOVIR; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ANAMNESIS; ANTIBIOTIC RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STAGING; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 33644746624     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/0XH7-F2V2-1K0R-NU2W     Document Type: Article

References (24)

1. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2005. Available at: http://aidsinfo.nih.gov/guidelines. Accessed October 10, 2005.
2. Gulick RM, Mellors JW, Havlir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine, Ann Intern Med. 2000;133:35-39.
3. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA. 1998;280:35-41.
4. Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS. 2001;15:2379-2384.
5. Moore R, Keruly J, Gebo K, Lucas G. Improvement in virologic, immunologic, and clinical outcomes in clinical practice from 1996 to 2002. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco. Abstract 558.
6. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000;182:1375-1384.
7. Montaner JS, Mellors JW. Antiretroviral therapy for previously treated patients. N Engl J Med. 2001;345:452-455.
8. Greenberg ML, Sista P, Miralles GD, et al. Enfuvirtide (T-20) and T-1249 resistance: observations from Phase II clinical trials of enfuvirtide in combination with oral antiretrovirals and a Phase I/II dose-ranging monotherapy trial of T-1249. In: Program and abstracts of the XI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications; June 8-11, 2004; Seville, Spain. Abstract 128.
9. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
10. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
11. Katlama C, Arastéh K, Clotet B, et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings. In: Program and abstracts of the 2nd International AIDS Society Meeting; July 13-16, 2003; Paris, France. Abstract LB2.
12. Trottier B, Arasteh K, Henry K, et al. Durability of response to enfuvirtide through 48 weeks in the TORO trials. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL. Abstract H-835.
13. Eron J, Delfraissy JF, Kuritzkes D, et al. Safety of enfuvirtide (ENF) through 48 weeks of therapy in the TORO trials. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL. Abstract H-836.
14. Arasteh K, Lazzarin A, Clotet B, et al. TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen. In: Program and abstracts of the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand.
15. Walmsley S, Clotet B, Cooper D, Lalezari J, Nelson M, et al. Efficacy of enfuvirtide in subgroups of patients through 48 weeks of therapy in the TORO trials. In: Program and abstracts of the 9th European AIDS Conference; October 25-29, 2003; Warsaw, Poland. Abstract 7.3/15.
16. Cahn P. for the RESIST-2 study team. 24-week data from RESIST-2: phase 3 study of the efficacy and safety of either tipranavir/ritonavir (TPV/r) or an optimised ritonavir (RTV)-boosted standard-of -care (SOC) comparator PI (CPI) in a large randomised multicentre trial in treatment-experienced HIV+ patients. In: Program and abstracts of the 7th International Congress on Drug Therapy in HIV Infection; UK; Glasgow. Abstract PL14.3.
17. Hicks C. for the RESIST-1 study team. RESIST-1: a phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Abstract H-1137a.
18. Katlama C, Berger D, Bellos N, et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA. Abstract 164LB.
19. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements - clinical considerations for accelerated and traditional approval. 2002. Available at: http://www.fda.gov/cder/guidance/3647fnl.pdf. Accessed August 29, 2003.
20. Deeks SG, Hellmann N, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis. 2005;179:1375-1381.
21. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
22. Tierney C, Lathey JL, Christopherson C, et al. Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J Infect Dis. 2003;187:144-148.
23. Haubrich R, DeMasi R, Thommes JA. Improved virologic response in three-class experienced patients when an active boosted protease inhibitor is combined with enfuvirtide (ENF). In: Program and abstracts of the 43rd Infectious Diseases Society of America Annual Meeting; October 6-9, 2005; San Francisco, CA. Poster 785.
24. Cooper D, Hicks C, Cahn P, et al. 24-week RESIST study analyses: The efficacy of tipranavir/ritonavir (TPV/r) is superior to lopinavir/ritonavir (LPV/r), and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen (OBR). In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA. Poster 560.